COMPANY PROFILE

Autotacbio

Explore full profile

We believe that the elimination of these

South KoreaFounded 2015Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Autotacbio

Autotac Bio is a biotechnology company focused on developing novel therapies for neurodegenerative diseases, cancer, metabolic diseases, and muscular dystrophy. The company leverages its proprietary AUTOTAC technology to selectively degrade disease-causing protein aggregates through autophagy, a natural cellular process for removing damaged components. Autotac Bio's core clients include pharmaceutical companies and research institutions seeking advanced treatments for complex diseases. Operating in the biopharmaceutical market, the company generates revenue through partnerships, licensing agreements, and direct sales of its therapeutic compounds. By targeting specific proteins and promoting cellular cleanup, Autotac Bio aims to provide groundbreaking treatments that address unmet medical needs.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: South Korea
Employees: 3
Open positions: None listed
Dealroom signal: 24.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Techbio, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Autotacbio.

See all news

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Apr 2020	$17M	$66M	Aju IB Investment	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Autotacbio website traffic

Latest recorded traffic for Autotacbio is 280 monthly website visits, down 47.2% over the last three months.

Latest monthly visits280 3-month web change-47.2%

Monthly website visitsMay 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PHPhoreMostA new-model drug discovery company based in Cambridge, UK	Pampisford, United Kingdom	Operational	31	$77M	$230M
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational
TATandemAIAn advanced technology company dedicated to reinventing drug discovery infrastructure	New York City, United States	Operational
COcoding.bioBuilding best-in-class cell therapies through automation and computation	Oxford, United Kingdom	Operational
PBPromatix BiosciencesMulti-omics platform for novel cancer therapeutics discovery	London, United Kingdom	Operational